Senti Biosciences Inc (nasdaq:SNTI) Share Price

Company Profile

Business description
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Contact
2 Corporate Drive
First Floor
South San FranciscoCA94080
USA
T: +1 650 239-2030
https://www.sentibio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
48

Recommended

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.

Joseph Taylor | 16 July 2025

Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.

Brian Colello, CPA | 16 July 2025

These companies are our top choices for investors wanting to boost Aussie exposure.

Simonelle Mody | 15 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,875.30	60.00	0.68%
CAC 40	7,766.21	41.96	-0.54%
DAX 40	24,060.29	100.35	-0.42%
Dow JONES (US)	44,023.29	436.36	-0.98%
FTSE 100	8,938.32	59.74	-0.66%
HKSE	24,590.12	386.80	1.60%
NASDAQ	20,677.80	37.47	0.18%
Nikkei 225	39,678.02	218.40	0.55%
NZX 50 Index	12,728.12	38.49	0.30%
S&P 500	6,243.76	24.80	-0.40%
S&P/ASX 200	8,630.30	59.90	0.70%
SSE Composite Index	3,505.00	14.65	-0.42%